Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DML51D0)

Drug Name
UCL-2000; butabindide Drug Info
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DML51D0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cholecystokinin receptor type A (CCKAR) TTCG0AL CCKAR_HUMAN Agonist [2]
Tripeptidyl-peptidase II (TPP2) TTQ7R2V TPP2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cholecystokinin receptor type A (CCKAR) DTT CCKAR 3.907 4.133 2.858 3.892
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Obesity
ICD Disease Classification 5B81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cholecystokinin receptor type A (CCKAR) DTT CCKAR 9.99E-01 -0.03 -0.2
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of University College London.
2 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.